Methods We investigated data of 613 children from the prospective TEDDY study who were persistent positive for IAA, GADA and/or IA2A autoantibodies. We used a novel approach of Bayesian joint modeling of longitudinal and survival data to assess the potentially time-and covariatedependent association between the longitudinal autoantibody titers and progression time to T1D. Results For all autoantibodies we observed a positive association between the titers and the T1D progression risk. This association was estimated as time-constant for IA2A, but decreased over time for IAA and GADA. For example the hazard ratio [95% credibility interval] for IAA (per transformed unit) was 3.38 [2.66, 4.38] at 6 months after seroconversion, and 2.02 [1.55, 2.68] at 36 months after seroconversion.
Introduction
Type 1 diabetes (T1D) is one of the most common chronic diseases in childhood, with worldwide increasing incidence [1] . The disease is preceded by a preclinical period of islet autoimmunity, which most commonly develops in early infancy [2, 3] . The presence of islet autoantibodies is associated with the progression to clinical diabetes [4] . However, the time from the first emergence of autoantibodies, called seroconversion, to the onset of clinical symptoms varies considerably between individuals, ranging from weeks to decades [4] .
It is also known that the combination of different autoantibodies as well as the autoantibody titer is associated with progression time [5] . For insulin autoantibodies (IAA), both their titers around seroconversion and their mean levels over time have been found to be associated with progression to T1D [2, 6] , and similar findings have been recently reported for other islet autoantibodies [7] [8] [9] . Nevertheless, detailed analyses of autoantibody titers over time are lacking.
Here, we investigated data of more than 600 islet-autoantibody-positive children followed up within the prospective The Environmental Determinants of Diabetes in the Young (TEDDY) study [10, 11] . In contrast to previous analyses, we used joint models of longitudinal and survival data. This class of models has the advantage to avoid potential bias due to characteristics of the longitudinal markers (here autoantibodies), such as random biological fluctuations, informative censoring and discrete measurement time points [12] . By applying a novel approach of joint modeling, we gained further insights into the potentially complex relationship between longitudinal islet-autoantibody measures and the time to T1D progression, particularly with respect to timevarying associations of both.
Methods
TEDDY is an ongoing prospective cohort study funded by the National Institutes of Health with the primary goal to identify environmental causes of T1D. The TEDDY study enrolled 8676 children with increased genetic risk for T1D who were recruited in six clinical research centers located in the USA, Finland, Germany and Sweden between 2004 and 2010 shortly after birth. Detailed information on study design, eligibility and methods has been previously published [11, 13, 14] . Written informed consents were obtained for all participants from a parent or primary caretaker, separately, for genetic screening and for participation in prospective follow-up before inclusion in the study. The study was approved by local Institutional Review or Ethics Boards and is monitored by the External Advisory Board formed by the National Institutes of Health. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5) . For this analysis, we used the data of all children who had developed one or more persistent islet autoantibodies by the time of our data access (December 31, 2014). At that time point the median age of the children analyzed at their last visit was 6.5 years with a range from 0.75 to 10.2 years.
Definition of islet autoimmunity
Development of persistent islet autoimmunity was assessed every 3 months and defined by the presence of at least one islet autoantibody among autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA) and insulinoma-associated protein 2 (IA2A) on two or more consecutive visits confirmed by two laboratories. Date of persistent autoimmunity to an autoantibody was defined as the draw date of the first sample of the two consecutive samples which deemed the child persistent confirmed positive for this autoantibody. As described in more detail elsewhere [7] , the respective autoantibody titers were standardized to be comparable across study laboratories (University of Bristol, UK; and University of Colorado, Denver, USA) by subtracting the laboratory-and antibody-specific threshold and dividing by the laboratory-and autoantibody-specific standard deviation and were log-transformed afterward.
Study outcome
The main outcome of this analysis was the time to development of T1D after seroconversion in months. T1D diagnosis was based on American Diabetes Association criteria [15] .
Statistical analyses
Of the 8676 children enrolled, 613 had developed one or more autoantibodies at the time of our data access. We created three subsets of the data where we restricted the data to children who had seroconverted to IAA (n = 442), GADA (n = 466) or IA2A (n = 288), respectively. These subsets were not mutually exclusive, as children had potentially seroconverted to multiple autoantibodies. Children were assigned to each subset irrespectively of whether the specific autoantibody was among the first islet autoantibodies to appear or appeared at a later time during follow-up. For example, if a child developed autoantibodies to IAA first and autoantibodies to GADA later, the child would be assigned to both the IAA and GADA subset.
We used a novel shared parameter joint model approach to assess the association between the longitudinal autoantibody titers from seroconversion with the time to T1D. Joint models allow the incorporation of longitudinal titers as timevarying covariates into the survival model of progression to T1D by estimating a longitudinal model and a proportional hazards model, using a joint likelihood for both submodels [16] . We further extended this model to a more flexible joint model, where we were able to assess heterogeneous and nonlinear individual biomarker trajectories and to explore complex associations between the biomarkers and the time to event [17] . We refer to Appendix for further details. Using this novel approach we specified the autoantibody titers over time as smooth, nonlinear, subject-specific trajectories in the longitudinal model. Furthermore we allowed the association between the modeled trajectories and the time to T1D to be time-varying in our main analysis. In additional explorative analyses we allowed the association to differ between subjects with different characteristics, and to differ over time between subjects with different characteristics.
We fitted these models for each of the three autoantibodies IAA, GADA and IA2A, separately, within each autoantibody-specific subset. In the longitudinal submodels, we assessed the associations of each autoantibody titer with (a) age at seroconversion of the respective autoantibody, (b) a binary variable indicating whether the autoantibody was among the first autoantibodies to appear, and (c) two timevarying binary variables indicating which of the other two autoantibodies were present at each observed time point. In each proportional hazards submodel, we assessed the associations of the smooth subject-specific autoantibody trajectories from the longitudinal model with progression time from seroconversion of the respective autoantibody to T1D. Baseline covariates were (a) the age at seroconversion of the respective autoantibody and (b) whether the autoantibody was among the first autoantibodies to appear. We further assessed whether the association between the autoantibody trajectories and the time to T1D differed over time between subjects with and without a first-degree relative with T1D or between girls and boys. Additionally we checked for differences in the association between HLA genotypes. Due to the limited size of certain HLA subgroups we modeled this association as time-constant.
All models were estimated within a Bayesian framework using the R-package bamlss [18] . Weakly informative normal priors were used for all coefficients. We report the posterior mean estimates/hazard ratios and 95% credibility intervals (CI) for all modeled parameters. Bayesian CIs can be interpreted as the interval in which the population parameter lies with a given probability (here 95%). We assessed convergence of the Markov chains by visual inspection of traceplots and conducted sensitivity analyses with regard to prior specification. All calculations were carried out with R version 3.2.5 [19] . Table 1 shows the study characteristics in each subset, i.e., the subsets of children who developed IAA, GADA or IA2A autoantibodies, respectively, at any time during follow-up. In most cases, either IAA, GADA or both were present at the time of the first seroconversion, whereas IA2A occurred at a later time point. The children seroconverted to the different autoantibodies at different median ages (p < 0.001, Kruskal-Wallis Test) with IAA seroconversion taking place at a lower median age. Apart from that, children with different autoantibodies were similar regarding the progression time to T1D and other variables.
Results
The individual autoantibody patterns over time after seroconversion were heterogeneous, but on average IAA titers declined after an initial increase, and GADA and IA2A titers increased shortly after seroconversion and remained relatively stable thereafter ( Supplementary Fig. 1 ).
In the joint modeling of autoantibody titers over time and the time to T1D, we observed for all autoantibodies a positive association between the titer and the risk of progression to T1D. Titers over time were lower for subjects who seroconverted at an older age for the respective autoantibody, and higher if the respective autoantibody appeared at the initial seroconversion, and if other autoantibodies were present (Table 2) . For each autoantibody, a higher age at the respective seroconversion was also associated with lower risk of progression to clinical T1D. For example, children had a hazard ratio [95% CI] of 0.84 [0.72, 0.98] if they seroconverted one year later for IAA.
We further investigated whether the association between the estimated trajectories of autoantibodies and the progression to T1D was time-varying or constant. By using our approach, we observed that the association was time-varying for IAA and GADA with the association being highest early after seroconversion and decreasing over time ( Fig. 1) in Fig. 1 , positive associations with T1D progression were observed for IAA up to 54 months after seroconversion, for GADA up to 18 months after seroconversion and for IA2A between 6 and 36 months after seroconversion. The traceplots indicated satisfactory convergence of the Markov chains ( Supplementary Figs. 2-4) , and sensitivity analyses showed robustness against different prior specifications ( Supplementary Fig. 5 ).
We further observed differences in the time-varying association of autoantibodies with progression to T1D between children with and without a first-degree relative with T1D. For all autoantibodies the associations were higher among children with a first-degree relative at early time points and decreased more strongly within this group (Fig. 2, upper panel) . For IAA, the associations between the two groups differed from seroconversion until about 12 months thereafter, as indicated by the credibility bands of the differences (Fig. 2, lower panel) , but only from 4 to 6 months after seroconversion for GADA and from 1 to 16 months after seroconversion for IA2A. For all autoantibodies HLA subgroups were similar in the association between autoantibody trajectories and the time to T1D (Fig. 3 ). An exception was a higher association for subjects with IAA autoantibodies and the DR3/3 genotype, a genotype which is less prevalent among IAA positive children (n = 30, 7%). In accordance with the difference in the hazard, the mean titer levels between progressors and non-progressors differed more strongly within the small subgroup of DR3/3 than within other HLA genotypes with non-progressors showing an especially low level (Supplementary Fig. 6 ). We did not observe consistent differences in the association over time between girls and boys ( Supplementary Fig. 7) .
Discussion
In the present study the complex relationship between longitudinally measured autoantibodies and the risk of progression to T1D diabetes was explored using a novel joint modeling approach. We observed potentially time-varying positive associations between the autoantibody titers of IAA and GADA, and the risk of T1D progression, indicating that the T1D progression risk associated with autoantibody titers was highest shortly after seroconversion of the respective autoantibody. The hazard ratio was highest for IAA, especially at early time points. Additionally, we observed that the associations of the autoantibody titer and the T1D risk early after seroconversion were more pronounced in children with first-degree relatives with T1D.
These results were in line with earlier results from other cohorts, where initial and mean IAA and IA2A titers were shown to be associated with the risk of progression [2, 6, 20] as well as from a more recent and methodologically advanced study based on the TEDDY data. In this study the relationship between titers of the same autoantibodies over time and the risk of progression to T1D was modeled assuming a time-constant association [7] . By using mean levels of the respective autoantibodies as time-varying predictors in a Cox model, the authors could show a positive association between autoantibody titers and the time to T1D progression for IAA and IA2A in their analyses.
Potential limitations of this previous approach are, however, that (a) only subject's mean titers until a certain time point are taken into account and not all observed values over time, (b) in a time-varying Cox model the time-varying predictor is assumed constant between observations, and (c) the association between autoantibodies and the risk of progression is assumed to be time-constant. These limitations were addressed by our joint modeling approach. Here, we flexibly modeled the trajectories of all three autoantibodies in each subject as a smooth function of time, i.e., obtaining predictions for the autoantibody titers between the measurements at discrete time points, and could use all this information as a time-varying covariate in the survival model. Additionally, we allowed their association with the risk of T1D progression to vary over time and between groups of subjects (children with and without first-degree relatives with T1D as well as boys and girls). In consequence, we were able to explore the association between autoantibodies and the risk of T1D beyond the previous results. For example, we observed that increased GADA titers may predict T1D progression within the first 1.5 years after seroconversion, but not thereafter. As this association averages to 0 over the whole time range this association was potentially not captured in the simpler modeling from the previous analysis. Furthermore, our modeling approach revealed that the time-varying associations appear to be more pronounced in children with first-degree relatives with T1D compared to children without.
The modeling of autoantibodies as longitudinal biomarkers and the time to clinical T1D poses a challenge due to the nature of the data beyond the aspects mentioned above. Longitudinal biomarkers usually contain potential random variation both due to the laboratory measurement process as well as short-and long-term biological fluctuations and are only observed until an event occurs. Whereas not accounting for the random fluctuations in a time-varying Cox model might result in an underestimation of the hazard ratio [12] , ignoring the latter might distort the estimation of covariate effects in the longitudinal model. By jointly analyzing the longitudinal and survival model we could address these issues and gained further insights as to how covariates affected both the autoantibody titers over time, and the risk of T1D progression. We found that earlier seroconversion for the respective autoantibody, if the respective seroconversion was the initial one, as well as the presence of other autoantibodies was associated with higher autoantibody titers. The age at the respective seroconversion was also inversely related to the risk of T1D progression for every autoantibody. While joint modeling approaches allow for detailed and unbiased estimations, they demand a high number of subjects, especially when complex associations are modeled in the survival part. TEDDY is the largest prospective study on the determinants of T1D worldwide and thus offers a unique opportunity to explore the application of joint modeling techniques on these complex relationships due to the high number of subjects and the detailed measurement schedule.
Currently, the presented flexible joint model only allows the assessment of one longitudinal biomarker at a time. In consequence, one limitation is that we were not able to combine all three markers into one joint model. We partly addressed this issue by including information on the presence of other autoantibodies and the order of their occurrence in our model. While they provide insights into the mechanisms of disease progression, a drawback of our results is that they cannot easily be translated from a cohort setting with frequent measurements into clinical practice, as the age at the respective seroconversion plays a crucial role in the prediction of T1D progression risk, but is not readily available in practice.
In conclusion, by using state of the art joint modeling techniques we were able to give insights into the complex relationship between longitudinal autoantibody titers and the risk of progression to clinical T1D. Risk stratification basing on autoantibody titers should focus on time points early after seroconversion.
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